血管紧张素受体阻滞剂对2型糖尿病合并糖尿病肾脏疾病患者肾脏和心血管结局疗效的性别差异:RENAAL和IDNT试验的事后分析
该研究基于RENAAL和IDNT试验的事后分析,纳入1737例男性和924例女性2型糖尿病合并糖尿病肾脏疾病患者,评估血管紧张素受体阻滞剂(氯沙坦和厄贝沙坦)对肾脏和心血管结局疗效的性别差异。结果显示,血管紧张素受体阻滞剂对肾脏结局的获益在男女间相似,但对心血管结局的获益仅在男性中显著,性别与治疗交互作用HR为1.37(95%CI 1.03, 1.82)。
要点
- 肾脏结局:男性HR 0.72(95%CI 0.59, 0.86),女性HR 0.86(95%CI 0.69, 1.06),性别与治疗交互作用HR 1.19(95%CI 0.89, 1.59)
- 心血管结局:男性HR 0.81(95%CI 0.69, 0.95),女性HR 1.11(95%CI 0.88, 1.40),性别与治疗交互作用HR 1.37(95%CI 1.03, 1.82)
- 作者认为需要更多关注血管紧张素受体阻滞剂疗效的性别差异及其反应差异的潜在机制
核心结论
- 在2型糖尿病合并糖尿病肾脏疾病个体中,血管紧张素受体阻滞剂对肾脏结局的获益在男性和女性中相似,但对心血管结局的获益仅在男性中显著。
- 作者认为需要更多关注血管紧张素受体阻滞剂疗效的性别差异及其反应差异的潜在机制。
研究设计与样本
- RENAAL(Angiotensin II Antagonist Losartan Study)和IDNT(Irbesartan type II Diabetic Nephropathy Trial)试验的事后分析。
- 纳入1737例男性参与者和924例女性参与者。
- 肾脏结局定义为终末期肾病或血清肌酐加倍首次事件的时间;心血管结局定义为卒中、心肌梗死、心血管死亡或心力衰竭住院复合终点首次事件的时间。
- 通过Cox比例风险模型中的性别×治疗交互项评估性别差异。
主要发现
- 血管紧张素受体阻滞剂对肾脏结局的获益在男性和女性参与者中相似:男性HR 0.72(95%CI 0.59, 0.86),女性HR 0.86(95%CI 0.69, 1.06),性别×治疗交互作用HR 1.19(95%CI 0.89, 1.59)。
- 对于心血管结局,血管紧张素受体阻滞剂降低男性风险但不降低女性风险:男性HR 0.81(95%CI 0.69, 0.95),女性HR 1.11(95%CI 0.88, 1.40),性别×治疗交互作用HR 1.37(95%CI 1.03, 1.82)。
关键数值与推荐
- 肾脏结局:男性HR 0.72(95%CI 0.59, 0.86) vs 女性HR 0.86(95%CI 0.69, 1.06),性别×治疗交互作用HR 1.19(95%CI 0.89, 1.59)。
- 心血管结局:男性HR 0.81(95%CI 0.69, 0.95) vs 女性HR 1.11(95%CI 0.88, 1.40),性别×治疗交互作用HR 1.37(95%CI 1.03, 1.82)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Our aim was to assess sex differences in the efficacy of angiotensin receptor blockers (i.e. losartan and irbesartan) on kidney and cardiovascular outcomes in individuals with type 2 diabetes and diabetic kidney disease. METHODS: Data from the Angiotensin II Antagonist Losartan Study (RENAAL) and Irbesartan type II Diabetic Nephropathy Trial (IDNT) were used. The kidney outcome was time to first event of end-stage kidney disease or doubling of serum creatinine. The cardiovascular outcome was time to first event of a composite of stroke, myocardial infarction, cardiovascular death or hospitalisation for heart failure. Sex differences were assessed by a sex × treatment interaction term in Cox proportional hazards models. RESULTS: Included were 1737 male participants and 924 female participants. The beneficial effect of angiotensin receptor blockers on the kidney outcome was similar between male and female participants (HR in male participants 0.72 [95% CI 0.59, 0.86] vs HR in female participants 0.86 [95% CI 0.69, 1.06]; sex × treatment interaction HR 1.19 [95% CI 0.89, 1.59]). For the cardiovascular outcome, angiotensin receptor blockers lowered the risk in male but not in female participants (HR in male participants 0.81 [95% CI 0.69, 0.95] vs HR in female participants 1.11 [95% CI 0.88, 1.40]; sex × treatment interaction HR 1.37 [95% CI 1.03, 1.82]). CONCLUSIONS/INTERPRETATION: This study in individuals with type 2 diabetes and diabetic kidney disease suggests that the beneficial effects of angiotensin receptor blockers are similar in male and female participants for the kidney outcome but not for the cardiovascular outcome. More attention to sex differences in angiotensin receptor blockers' efficacy and underlying mechanisms of differences in response is needed. TRIAL REGISTRATION: ClinialTrials.gov NCT00308347.
引用
- de Vries ST, Pena MJ, Tye SC, et al. Sex differences in the efficacy of angiotensin receptor blockers on kidney and cardiovascular outcomes among individuals with type 2 diabetes and diabetic kidney disease: post hoc analyses of the RENAAL and IDNT trials. Diabetologia. 2024. PMID: 39656268. doi:10.1007/s00125-024-06325-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。